The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
 
Jonathan Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Andrew Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Kymera; Pharmaessentia; SERVIER
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst); Sumitomo Pharma Oncology (Inst)
 
Steven Attia
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BTG (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Guardant Health; Incyte (Inst); InhibRx (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Monopar Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); Salarius Pharmaceuticals (Inst); Shanghai Pharma (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
 
Mark Agulnik
Speakers' Bureau - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Genzyme; Lilly
 
Breelyn Wilky
Consulting or Advisory Role - AADi; Adcendo; Boehringer Ingelheim; Deciphera; Epizyme; InhibRx; Polaris; SpringWorks Therapeutics
Research Funding - Exelixis
Travel, Accommodations, Expenses - Agenus
 
William Tap
Leadership - AstraZeneca; Atropos; Avacta Life Sciences; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Aadi; Abbisko Therapeutics; Avacta Life Sciences; Bayer; Boehringer Ingelheim; C4 Therapeutics; Curadev; Daiichi Sankyo; Deciphera; Ikena Oncology; IMGT; inhibrx; Ipsen; PharmaEssential; Ratio; Servier; Sonata
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); servier (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Molleculin
Consulting or Advisory Role - deciphera
Research Funding - ASCO (Inst); Deciphera (Inst); IDRx (Inst); Novartis (Inst); Solaris Health (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - NCCN
 
Elizabeth Davis
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Aadi; Deciphera
Speakers' Bureau - Physicans' Education Resource
Research Funding - Actuate Therapeutics (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); TopAlliance BioSciences Inc (Inst)
 
Liangxing Zou
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Nisha Shah
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Kevin Moynihan
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Julia Lawrence
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Lei Sun
Employment - Cogent Biosciences
Stock and Other Ownership Interests - Cogent Biosciences
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Boehringer Ingelheim; Deciphera; Ipsen; Replimune
Research Funding - Advenc (Inst); Ascentage Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Karyopharm Therapeutics (Inst)